Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O' Rourke L, Dimopoulos MA.

Haematologica. 2019 Jun 20. pii: haematol.2019.217448. doi: 10.3324/haematol.2019.217448. [Epub ahead of print]

2.

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Plesner T, Arkenau HT, Gay F, Minnema MC, Boccadoro M, Moreau P, Cavenagh J, Perrot A, Laubach JP, Krejcik J, Ahmadi T, de Boer C, Chen D, Chiu C, Schecter JM, Richardson PG.

Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31. No abstract available.

PMID:
30931524
3.

Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.

Salles G, Gopal AK, Minnema MC, Wakamiya K, Feng H, Schecter JM, Wang M.

Clin Lymphoma Myeloma Leuk. 2019 May;19(5):275-284. doi: 10.1016/j.clml.2018.12.013. Epub 2019 Jan 2.

PMID:
30795996
4.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV.

Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20.

5.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

6.

Response to "The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma".

Xu XS, Schecter JM, Jansson R, Yan X.

Clin Pharmacol Ther. 2017 Dec;102(6):905. doi: 10.1002/cpt.779. Epub 2017 Jul 29. No abstract available.

7.

Response to: Interference of daratumumab on the serum protein electrophoresis.

McCudden C, Axel AE, Slaets D, Dejoie T, Clemens P, Frans S, Bald J, Plesner T, Jacobs JF, van de Donk NW, Moreau P, Schecter JM, Ahmadi T, Sasser AK.

Clin Chem Lab Med. 2017 Feb 1;55(2):e29-e30. doi: 10.1515/cclm-2016-1026. No abstract available.

PMID:
27930366
8.

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.

McCudden C, Axel AE, Slaets D, Dejoie T, Clemens PL, Frans S, Bald J, Plesner T, Jacobs JF, van de Donk NW, Moreau P, Schecter JM, Ahmadi T, Sasser AK.

Clin Chem Lab Med. 2016 Jun 1;54(6):1095-104. doi: 10.1515/cclm-2015-1031.

9.
10.
11.

Open-label tiagabine monotherapy for major depressive disorder with anxiety.

Carpenter LL, Schecter JM, Tyrka AR, Mello AF, Mello MF, Haggarty R, Price LH.

J Clin Psychiatry. 2006 Jan;67(1):66-71.

PMID:
16426090
12.

Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants.

Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH.

J Clin Psychiatry. 2005 Oct;66(10):1234-8.

PMID:
16259536
13.

Service expectations and clinical characteristics of patients receiving psychiatric emergency services.

Carpenter LL, Schecter JM, Underwood JA, Tyrka AR, Price LH.

Psychiatr Serv. 2005 Jun;56(6):743-5.

PMID:
15939953
14.

A case series describing orlistat use in patients on psychotropic medications.

Carpenter LL, Schecter JM, Sinischalchi J, Leon Z, Price LH.

Med Health R I. 2004 Dec;87(12):375-7. No abstract available.

PMID:
15679228

Supplemental Content

Loading ...
Support Center